Thrombotic Microangiopathy *Clinicopathological Correlations*


Wesam Ismail, MD Prof. of Pathology Head of Pathology Department Beni-Suef University

Thrombotic Microangiopathy

- A pathological lesion observed in a wide spectrum of diseases
- Triggered by endothelial injury and/or dysfunction
- The term thrombotic microangiopathy (TMA) was first introduced by Symmers in 1952, defining <u>a lesion of</u>:
 - vessel wall thickening (mainly arterioles or capillaries) with swelling or detachment of the endothelial cell from the basement membrane
 - accumulation of fluffy material in the subendothelial space
 - intraluminal platelet thrombosis
 - partial or complete obstruction of the vessel lumina

Thrombotic Microangiopathy

A histopathological (morpholgical) term that defines glomerular, arteriolar or interlobular artery lesions and is characterized by a patchy distribution




Box 1. Conditions Associated With TMA

- ADAMTS13-mediated TMA (TTP)
 - Congenital (cTTP)
- Complement-mediated TMA (aHUS)
 - Congenital
 - Immune
- Coagulation-mediated TMA (pathogenic variants in PLG, THBD, and DGKE)
- Metabolic (defects of cobalamin metabolism)
- Infection-associated TMA
 - Bacterial: Shiga toxin-producing Escherichia coli, Streptococcus pneumoniae, Campylobacter jejuni, Klebsiella pneumoniae
 - Viral: influenza, HIV, EBV, CMV, BK virus, parvovirus B19, SARS-CoV-2
 - Fungal: histoplasmosis
- Pregnancy-associated TMA
- Preeclampsia
- HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome
- Trigger of TTP, aHUS, CAPS
- Drug-induced TMA
 - Immune mediated
 - Via drug-triggered antibodies against platelets/neutrophils: gemcitabine, oxaliplatin, trimethoprim-sulfamethoxazole, quinine, vancomycin
 - Via autoantibodies against ADAMTS13: ticlopidine
 - Non-immune mediated
 - Chemotherapy: alemtuzumab, gemcitabine, mitomycin C, vincristine, doxorubicin, pentostatin, VEGF inhibitors, tyrosine kinase inhibitors, proteasome, and checkpoint inhibitors
 - Immunosuppressive therapy: calcineurin inhibitor, sirolimus, interferon β
 - Antibiotics: ciprofloxacin, levofloxacin, metronidazole, nitrofurantoin, penicillin
 - Other: cocaine, ecstasy, estrogen/progesterone, anti-inflammatories, oxymorphone, simvastatin
- Transplant-associated TMA
 - Solid organ
 - Hematopoietic stem cell transplant
- Malignancy-associated TMA
- Solid: breast, gastric, lung, ovarian, prostate, and urothelial cancers
- Hematologic: Myelo and lymphoproliferative, monoclonal gammopathies (myeloma, smouldering myeloma, MGRS), and POEMS
- Autoimmune diseases
- APS, including CAPS

- Primary glomerulonephritis and vasculitis (observed on biopsy)
- Sjögren syndrome, rheumatoid arthritis, dermatomyositis
- Hypertensive emergency
- Other: hemophagocytic lymphohistiocytosis, sickle cell disease, Castleman disease and variants

Pathogenesis

Direct Endothelial Damage



Modified from Keir L, Coward RJ - Pediatr. Nephrol. (2010)

Thrombotic Microangiopathy

Typically:

- Thrombocytopenia
- Microangiopathic hemolytic anemia (MAHA)
- Organ Injury , frequently AKI

The kidney is the most frequently injured organ, but other systems including the central nervous system, the cardiovascular and respiratory systems, and the gastrointestinal tract may also be affected

Depending on the organ primarily involved clinical symptoms may vary considerably from mild to severe

Associated with significant morbidity and mortality (early recognition)

Thrombotic Microangiopathy

Renal limited forms


- Frequently encountered in clinical practice
- can be diagnostically challenging, often delaying the initiation of targeted therapy
- Observed more often in the setting of GN (ANCA-associated vasculitis, IgA nephropathy, MGN, FSGS), solid organ transplantation and in drug-induced TMA

Pathological features in the Kidney


Depend upon type , degree and the stage of injury (early versus late)

- In the kidney (native and transplant) interlobular arteries, afferent arterioles and glomerular capillaries are typically affected
- Can be divided into acute and chronic lesions
- Glomerular, Arteriolar/Arterial dominant or Glomerular & arteriolar/arterial

Do not distinguish between the multiple disease entities associated with TMA





endothelial cell injury/endothelial swelling




Inflammation, congestion

Intravascular congestion & red Cell fragmentation










occasional thrombus formation (not a must)

Differential Diagnosis MPGN (cryo)






endothelial swelling and detachment from the underlying GBM




Subendothelial expansion


Lumen



Mesangiolysis and capillary microanuerysm





• Subendothelial new basement membrane formation resulting in global or segmental duplication of glomerular basement membranes




• Subendothelial new basement membrane formation resulting in global or segmental duplication of glomerular basement membranes

 Subendothelial new basement membrane formation resulting in global or segmental duplication of glomerular basement membranes







Vascular (Acute) Endothelial Swelling



Vascular


Endothelial swelling and red cell fragmentation






Vascular

Mucoid Intimal swelling




Differential Diagnosis

> MPGN




Differential Diagnosis

> Transplant Glomerulopathy versus Chronic TMA




Classification




Different Nomenclature leads to difficult interpretation

Classification

Current approach



Brocklebank et al. Clin J Am Soc Nephrol 13, March, 2018



TMA & Monoclonal Gammopathy

- New data from the Mayo Clinic indicate that the association of TMA with monoclonal gammopathies is far more frequent than previously appreciated
- Of 146 patients with TMA, monoclonal immunoglobulin in 20 patients (13.7%)
- Among patients 50 and older, the prevalence of monoclonal gammopathy was 21%, which is approximately five-fold higher than the 4.2% expected rate in this population.
- Fifteen patients had monoclonal gammopathy of undetermined significance, one had multiple myeloma, one with smoldering myeloma, two had POEMS syndrome, and one had T-cell lymphocytic leukemia
- > Hypothesis:
 - Direct endothelial injury by the M-protein (more susceptible to the development of TMA after another insult)
 - indirectly via functional inhibition of proteins that regulate thrombosis

Kidney International (2017) 91, 691–698

Prognosis

- Degree of histologic damage rather than initial clinical severity is the best predictor of long-term prognosis
- Three main patterns that correlate with long term prognosis
 - Renal glomerular compartment (young children, good prognosis)
 - Dominating arterial compartment (older children and adults, poor prognosis)
 - Adults with both glomerular and vascular involvement (poor prognosis)
- Severity (cortical necrosis, TMA involving >50% of glomeruli at time of presentation)
- Stage: Early (potentially reversible) have to be distinguished from late (irreversible) "sclerosing" changes, Segmental sclerosis was associated with decreased GFR long term

Complete diagnostic algorithm for thrombotic microangiopathy

AJKD Vol 81 | Iss 5 | May 2023

ТМА	 MAHA: anemia, thrombocytopenia, reticulocytosis, elevated LDH and bilirubin, low haptoglobin, and/or schistocytes Exclude alternate diagnosis: autoimmune hemolytic anemia (direct antiglobulin test), disseminated intravascular coagulopathy (coagulation parameters, p-dimer, fibrinogen) Assess renal and extrarenal end-organ involvement
Exclude TTP	 Evaluate ADAMTS13 activity If ADAMTS13 activity < 10% → Evaluate the presence of autoantibodies against ADAMTS13
Exclude infection	 Stool toxin, cultures, imaging Viral testing, including HIV According to clinical presentation: viral PCR (Influenza A/B, COVID-19, BK virus, CMV)
Exclude secondary	 Autoimmune screen: ANA, dsDNA, ENA, APLA, RF, ANCA, anti-GBM Metabolic: Vitamin B₁₂, MMA and homocysteine Pregnancy test, transplant rejection markers
СМ-ТМА	 Functional assays: CH50, AH50, hemolytic assay#, CFH assay# Genetic testing: CFI, CFI, CFB, MCP, CFHR1-5, C3, THBD*, DGKε*, PLG* Complement proteins: CFB, CFH, CFI, C5, MCP#, properdin#, C3c, C3d, Bb, sC5b-9 Autoantibodies: anti-CFH

Take Home Message

> TMA is a descriptive and a non specific morphological term...

.....it is NOT a disease

- The pathologist can report suggestive features
- It is important to identify the underlying cause of the histologically observed "TMA", as some of them could be managed

TMA is NOT HUS/TTP

THANKYOU